

BIOTELEMETRY, INC.  
Form 8-K  
May 04, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 3, 2018

(Exact name of registrant as specified in its charter)

Delaware                                      000-55039      46-2568498  
(State or other jurisdiction      (Commission      (I.R.S. Employer  
of incorporation)                      File Number)      Identification No.)

1000 Cedar Hollow Road                                      19355  
Malvern, Pennsylvania  
(Address of principal executive offices)      (Zip Code)

Registrant's telephone number, including area code: (610) 729-7000

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. o

---

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 3, 2018, BioTelemetry, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders adopted the following proposals and cast their votes as described below.

Proposal 1

Election of two Class II director nominees to hold office until the 2021 Annual Meeting of Stockholders or until their successors are elected and qualified:

	For	Against	Abstained	Broker Non-Vote
Anthony J. Conti	21,733,773	806,147	24,642	4,517,605
Kirk E. Gorman	22,207,955	332,412	24,195	4,517,605

Proposal 2

Vote on an advisory resolution to approve the compensation of the Company’s named executive officers:

	For	Against	Abstained	Broker Non-Vote
	21,761,514	759,525	43,523	4,517,605

Proposal 3

Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered accounting firm for the year ending December 31, 2018:

	For	Against	Abstained	Broker Non-Vote
	25,828,171	1,214,928	39,068	—

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioTelemetry, Inc.

May 4, 2018 By: /s/ Peter Ferola

Name: Peter Ferola

Title: Senior Vice President and General Counsel